8-OH-PBZI

8-OH-PBZI
Clinical data
ATC code	none;
Identifiers
	IUPAC name (3aS,9bR)-3-propyl-1,2,3a,4,5,9b-hexahydrobenzo[e]indol-8-ol;
PubChem CID	10353845;
ChemSpider	8529297 ;
Chemical and physical data
Formula	C15H21NO
Molar mass	231.333 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCN1CC[C@H]2[C@@H]1CCC3=C2C=C(C=C3)O;
	InChI InChI=1S/C15H21NO/c1-2-8-16-9-7-13-14-10-12(17)5-3-11(14)4-6-15(13)16/h3,5,10,13,15,17H,2,4,6-9H2,1H3/t13-,15+/m1/s1 ; Key:LJDRQPOQHHOXHM-HIFRSBDPSA-N ;
	(verify)

8-OH-PBZI is a drug used in scientific research which acts as a potent and selective agonist for the dopamine D₃ receptor.^[1]^[2]^[3]

References

^ Scheideler, MA; Martin, J; Hohlweg, R; Rasmussen, JS; Naerum, L; Ludvigsen, TS; Larsen, PJ; Korsgaard, N; Crider, AM; Ghosh, D; Cruse, SF; Fink-Jensen, A (1997). "The preferential dopamine D3 receptor agonist cis-8-OH-PBZI induces limbic Fos expression in rat brain". European Journal of Pharmacology. 339 (2–3): 261–70. doi:10.1016/S0014-2999(97)01372-1. PMID 9473144.
^ Fink-Jensen, A; Nielsen, EB; Hansen, L; Scheideler, MA (1998). "Behavioral and neurochemical effects of the preferential dopamine D3 receptor agonist cis-8-OH-PBZI". European Journal of Pharmacology. 342 (2–3): 153–61. doi:10.1016/S0014-2999(97)01494-5. PMID 9548380.
^ Malik, P; Andersen, MB; Peacock, L (2004). "The effects of dopamine D3 agonists and antagonists in a nonhuman primate model of tardive dyskinesia". Pharmacology, Biochemistry, and Behavior. 78 (4): 805–10. doi:10.1016/j.pbb.2004.05.019. PMID 15301939.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.